Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof-of-concept clinical trial of BLU-554 in combination with CS1001 as a first-line treatment in patients with hepatocellular carcinoma in China

Trial Profile

A proof-of-concept clinical trial of BLU-554 in combination with CS1001 as a first-line treatment in patients with hepatocellular carcinoma in China

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CS 1001 (Primary) ; Fisogatinib (Primary)
  • Indications Liver cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 15 Aug 2019 According to CStone Pharmaceuticals media release, In June 2019, company received approval to initiate clinical trial of CS1001 in combination with fisogatinib (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma ("HCC") in China.
    • 01 Aug 2019 According to Blueprint Medicines media release, this trial is expected to initiate by the end of 2019.
    • 01 Aug 2019 According to Blueprint Medicines media release, nder Blueprint Medicines' collaboration with CStone Pharmaceuticals, the China National Medical Products Administration granted approval to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top